# STANFORD UNIVERSITY: Donor Derived CD19/CD22 CAR T Cells as Concurrent Therapy Against Relapse in Adults with B-ALL

**Lab Budget Score:** 55/100

| Field | Value |
|---|---|
| Organization | STANFORD UNIVERSITY |
| Location | STANFORD, CA |
| Project | Donor Derived CD19/CD22 CAR T Cells as Concurrent Therapy Against Relapse in Adults with B-ALL |
| Project number | 5P01CA049605-35 |
| Mechanism | P01 |
| Institute | National Cancer Institute |
| Award | $472,379 |
| Awarded | 2026-09-17 |
| Project period | 1997-05-01 to 2030-08-31 |
| UEI | HJD6G4D6TJY5 |

## Why this score
- Award of $400K or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11400088). Last refreshed: 2026-11-04T21:37:56.465Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.